Related by context. All words. (Click for frequent words.) 85 treatment naive genotype 75 HCV SPRINT 74 chronic HCV genotype 74 relapsed MM 72 CCR5 tropic HIV 71 alfa 2a 71 virus HCV infection 71 multicenter Phase 71 HCV NS5B polymerase 71 null responder HCV 71 Initiate Phase 71 #mg QD [002] 71 CYT# potent vascular disrupting 71 novel VDA molecule 71 HCV RESPOND 2 70 CCR5 mAb 70 naïve HCV 70 naive HCV 70 naive HCV genotype 70 blinded randomized placebo controlled 70 ug dose 70 forodesine 70 antiretroviral naïve 70 Initiated Phase 70 stage IIIb IV 70 humanized interleukin 6 70 relapsing remitting MS RRMS 70 mg TID 70 mg q#h 70 LymphoStat B belimumab 70 Amgen Neulasta ® 70 oral ridaforolimus 70 Naive Patients 70 INSPIRE Trial Phase III 70 Randomized Phase 70 infliximab monotherapy 70 multicenter Phase II 70 dosing cohorts 70 nucleotide analog 70 lintuzumab SGN 70 nucleoside naive 69 de novo kidney transplant 69 HIV coinfected 69 genotype 1b 69 ACTEMRA TM 69 placebo controlled Phase 69 multicenter Phase III 69 hepatitis C genotype 69 registrational Phase 69 dose escalation clinical 69 DEB# 69 LUX Lung 69 evaluating tivozanib 69 budesonide foam 69 NS5b 69 RECORD1 69 phase IIb study 69 RG# ITMN 69 EOquin TM phase 68 antiretroviral naive 68 relapsed refractory multiple myeloma 68 HCV genotypes 68 Omacetaxine 68 non nucleoside inhibitor 68 Amgen Neulasta R 68 systemic Phase 1b 68 mg QD 68 telaprevir dosed 68 Pivotal Phase 68 Budesonide foam crofelemer 68 telaprevir VX 68 patients coinfected 68 Aflibercept 68 HBeAg + 68 HCV genotype 68 recurrent glioma 68 refractory cutaneous T 68 KRAS mutations occur 68 VFEND 68 pegylated interferon alfa 2a 68 Peg IFN 68 oropharyngeal candidiasis OPC 68 LEXIVA r 68 e antigen HBeAg 68 virologically suppressed 68 oral deforolimus 68 MKC# MT 68 lead Aganocide compound 67 Bayer HealthCare Onyx Pharmaceuticals 67 μg dose 67 PRECiSE 67 trastuzumab Herceptin R 67 LymphoStat B TM 67 FOLFIRI chemotherapy 67 Phase Ib IIa 67 recurrent glioblastoma multiforme 67 PEG INTRON R 67 galiximab 67 HCV genotype 1 67 Phase Ib clinical 67 #mg BID [001] 67 acyclovir Lauriad R 67 ceftazidime 67 Phase Ib II 67 BARACLUDE ® 67 TMC# C# 67 REVIVE Diabetes 67 Xeloda ® 67 q#h 67 R# #mg BID 67 hepatitis C HCV 67 recombinant PSMA vaccine 67 BENCHMRK 67 virus HCV protease inhibitor 67 Hormone Refractory Prostate Cancer 67 mg administered orally 67 phase Ib 67 BRIM2 67 CIMZIA TM 67 MAGE A3 ASCI 67 dose cohort 67 q8h 67 ribavirin RBV 67 Crofelemer budesonide foam 67 Testosterone MDTS R 67 agonistic human 67 Albuferon TM 67 dose escalation Phase 67 IMiDs ® 67 8mg/kg 67 toenail onychomycosis 67 underwent liver transplantation 67 refractory CLL 67 Folfox 67 Achieves Primary Endpoint 67 ALN VSP Phase 67 Peginterferon 67 CTAP# Capsules 67 Phase 2b Clinical Trial 67 mcg BID 67 pegylated interferon alpha 67 CIMZIA TM certolizumab pegol 67 chronic HCV infection 67 mcg albinterferon alfa 2b 67 symptomatic BPH 67 R rilonacept Injection 67 TG MV 67 CCX# B 67 Second Pivotal Phase 67 Trial Evaluating 67 antibody MAb 66 HGS ETR1 mapatumumab 66 investigational protease inhibitor 66 dose escalation phase 66 assessing T DM1 66 mitoxantrone plus 66 ascending dose 66 Phase III Pivotal 66 achieved sustained virologic 66 refractory chronic lymphocytic 66 plus Copegus R 66 Chronic Hepatitis C 66 Ophena TM 66 Systemic Sclerosis 66 docetaxel Taxotere R 66 blinded placebo controlled 66 oral rivaroxaban 66 plus dexamethasone 66 HCV infected 66 randomized multicenter trial 66 evaluating mipomersen 66 TransVax ™ 66 non splenectomized 66 retinal vein occlusion induced 66 sorafenib tablets 66 MT# MEDI 66 BRIM3 66 phase IIb clinical 66 evaluable subjects 66 Combination REOLYSIN R 66 Pegasys plus Copegus 66 weekly subcutaneous injections 66 VEGFR2 inhibitor 66 pegylated interferon peg IFN 66 ongoing Phase 1b 66 fistulizing Crohn disease 66 Initiates Phase II 66 EOquin TM 66 rALLy clinical trial 66 HCV Genotype 66 Heterozygous Familial Hypercholesterolemia 66 Valopicitabine 66 Oral NKTR 66 huN# DM1 66 Engerix B 66 mg RDEA# 66 Mg Usa 66 IMiDs ® compound 66 papillary renal cell carcinoma 66 evaluating T DM1 66 Oral Fingolimod 66 PEG IFN 66 metastatic GIST 66 certolizumab 66 comparator arm 66 visilizumab 66 leukemia AML 66 Meets Primary Endpoint 66 somatostatin analog 66 ritonavir boosted 66 recurrent malignant glioma 66 anti PlGF 66 azathioprine monotherapy 66 myocardial infarction ventricular fibrillation 66 COU AA 66 Randomized Phase II 66 multicenter phase 66 oral FTY# 66 AEG# 66 Ozarelix 66 oral nucleoside analogue 66 cisplatin gemcitabine 66 orally administered inhibitor 66 PORxin TM platforms 66 NS5B polymerase 66 class mGluR5 inhibitor 66 omega interferon 66 FluCAM arm 66 reduce serum phosphate 66 CTA# Injection 65 recurrent metastatic ovarian cancer 65 achieved ACR# 65 randomized controlled Phase 65 Mg Uk 65 Phase 1b 65 PROSTVAC VF 65 topical gel formulation 65 ritonavir boosted atazanavir 65 decompensated liver disease 65 refractory NSCLC 65 mg qd 65 daily Infergen 65 receiving INTRON 65 prednisone prednisolone plus 65 underwent surgical resection 65 novel orally inhaled 65 demonstrated antitumor activity 65 REVIVE TA 65 stated Michelle Berrey 65 aflibercept VEGF Trap 65 dasatinib Sprycel ® 65 BARACLUDE R 65 receptor tyrosine kinase inhibitor 65 Neulasta R 65 humanized therapeutic 65 Pharmacokinetics PK 65 PRN FDA Approves 65 ABSORB clinical 65 G#DT 65 peginterferon alpha 2a 65 YONDELIS 65 HBeAg negative patients 65 dose dose escalation 65 designated HVTN 65 PRTX 65 myelodysplastic myeloproliferative diseases 65 including eniluracil ADH 65 kidney urologic 65 GOUT 65 TMC# [002] 65 AN# topical anti 65 GVAX ® 65 plus gemcitabine 65 PSMA ADC 65 systemic ALCL 65 brivanib 65 human IgG1 monoclonal 65 Perifosine KRX 65 SinuNase TM 65 inflammatory PDE 65 recurrent metastatic 65 placebo controlled dose escalation 65 Phase 2a trial 65 SPRYCEL ® 65 5 fluorouracil leucovorin 65 lopinavir r arm 65 Brentuximab Vedotin SGN 65 brand ciclesonide HFA 65 HGS ETR2 65 STEALTH C 65 sorafenib Nexavar ® 65 Pivotal Phase III 65 HBeAg positive 65 Peginterferon Alfa 2a 65 Phase IIIb clinical 65 label multicenter 65 relapsed multiple myeloma 65 Daclizumab 65 Bezielle 65 Hsp# Inhibitor 65 tramiprosate Alzhemed TM 65 interferon ribavirin 65 bevirimat Study 65 COPEGUS ribavirin 65 mg/m2 dose 65 Phase 1b clinical 65 dosing cohort 65 Phase IIb Trial 65 abacavir lamivudine 65 evaluating tesamorelin 65 develop HBV reactivation 65 GetGoal Phase III 65 Phase IIA 65 unresectable stage 65 Sapacitabine 65 RELOVAIR ™ 65 controlled dose escalation 65 PREZISTA r 65 subcutaneous PRO 65 pegylated interferon alpha 2a 65 histologically confirmed 65 ChronVac C R 65 Raptiva r 65 Empatic ™ 65 mg/m2 administered 65 Successfully Completes Phase 65 doripenem 65 ORENCIA ® 65 COPEGUS R 65 cutaneous T 65 Parathyroid Hormone 65 ALN HPN 65 CIMZIA ™ 65 investigational oral hepatitis C 65 PI3K/Akt pathway inhibitor 65 Phase 1b clinical trials 65 HBeAg negative 65 Phase 1b trial 65 low dose cytarabine 65 Epothilone D 64 Amigal TM 64 lenalidomide Revlimid R 64 pegylated alpha interferon 64 virus HCV 64 Commences Phase 64 ® bortezomib 64 biologic DMARD 64 rituximab refractory 64 plus prednisone prednisolone 64 microgram kg 64 Telik logo TELINTRA 64 Aptivus ® 64 FOLFOX6 chemotherapy regimen 64 phase IIb trial 64 CLL SLL 64 HuMax EGFr 64 dependent kinase inhibitor 64 potent triglyceride lowering 64 oral prodrug 64 Viread tenofovir disoproxil fumarate 64 stage IIIB 64 HCD# [002] 64 nitazoxanide 64 ® lenalidomide 64 PegIFN RBV 64 Treatment Naive Patients 64 erlotinib Tarceva ® 64 CAMMS# 64 receptor inhibiting monoclonal 64 Glufosfamide 64 Copegus ribavirin 64 docetaxel Taxotere ® 64 dose escalation trial 64 intravenous belinostat 64 approved incretin mimetic 64 genotypic resistance 64 Pentacel R 64 phase III isavuconazole 64 vaccinated PNH patients 64 Elotuzumab 64 virus HBV 64 ara C 64 metastatic neuroendocrine tumors 64 μg doses 64 elotuzumab 64 mertansine 64 alvespimycin 64 Myelodysplastic Syndrome MDS 64 bone marrow reticulin deposition 64 metastatic hormone refractory 64 APPRAISE 64 Initiates Enrollment 64 PEGylated Fab fragment 64 chronic HCV 64 Pooled Analysis 64 maximally tolerated dose 64 comparing XIENCE V 64 underwent resection 64 ASG 5ME dacetuzumab SGN 64 LEUKINE 64 VP# [004] 64 AAG geldanamycin analog 64 Sudhir Agrawal D.Phil 64 IMPACT DCM 64 peginterferon alfa 2b 64 aplastic anemia AA 64 tenofovir emtricitabine 64 TO AVOID PREGNANCY WHILE 64 Complicated Skin 64 Kit CD# positive 64 cilengitide 64 plus OBT 64 PEGINTRON TM 64 azilsartan medoxomil 64 selective phosphodiesterase 64 recurrent genital herpes 64 Hepatitis C HCV 64 hour bronchodilation 64 ABSSSI 64 Completes Patient Enrollment 64 undergoing elective percutaneous 64 oral levofloxacin 64 Peginterferon alfa 2b 64 PREZISTA ritonavir 64 Infusion Reactions Severe 64 neutropenia dehydration dyspnea 64 CALGB # [002] 64 plus methotrexate 64 Relapsed Refractory 64 relapsed refractory AML 64 Teriflunomide 64 adecatumumab MT# 64 Phase IIb clinical trials 64 undetectable hepatitis C 64 mg kg BID 64 achieved CCyR 64 placebo controlled Phase III 64 EDEMA3 64 CML CP 64 Contrave# 64 ZACTIMA 64 BR.# 64 #mg dose [002] 64 vapreotide acetate 64 PrevOnco ™ 64 includes TOLAMBA TM 64 Tipranavir 64 Pegasys ® 64 ® natalizumab 64 HCV RNA polymerase 64 Proellex TM 64 catheter occlusion 64 Relapsed Multiple Myeloma 64 alpha folate receptor 64 solithromycin 64 Phase 2a clinical 64 initiated Phase Ib 64 Xelox 64 R sorafenib tablets 64 Alocrest 64 Amrubicin 64 Allovectin 7 R 64 PEG interferon 64 MEK Inhibitor 64 nucleotide analogue 64 Infected Patients 64 markets Testim ® 64 intravenous bolus 64 Nitazoxanide 64 methylnaltrexone bromide 64 ExTRACT TIMI 64 CHAMPION PCI 64 Phase III placebo controlled 64 hepatocellular cancer 64 phase IIa clinical 64 gemcitabine carboplatin 64 pharmacogenomic translational research 64 phase IIa 64 oral ghrelin agonist 64 intravenous RSD# 64 metaglidasen 64 AKT inhibitor 64 Ribavirin causes 64 vinorelbine tartrate 64 REMICADE monotherapy 64 pegIFN 64 Randomized Double Blind 64 sunitinib malate 64 oral picoplatin 64 continuous intravenous infusion 64 Ecallantide 64 Testosterone MDTS ® 64 SNT-MC#/idebenone 64 #mg ATC 64 oral Janus kinase 63 unique alkylating agent 63 Lymphocytic 63 biochemical relapse 63 Phase 1a clinical 63 VELCADE melphalan 63 compound INCB# 63 refractory chronic myeloid 63 IIa clinical trials 63 PLX STROKE targeting 63 metastatic CRC 63 cisplatin vinorelbine 63 dexamethasone Decadron 63 micafungin 63 FUSILEV enhances 63 controlled multicenter Phase 63 Vaccine Adjuvant 63 rapid virologic response 63 REYATAZ r arm 63 nosocomial pneumonia 63 ELACYT 63 RSD# oral 63 Fludara ® 63 generation DACH Platinum 63 #mg q8h 63 GW# [003] 63 thetreatment 63 interferon gamma 1b 63 piperacillin tazobactam 63 multicenter randomized placebo controlled 63 VICTOR E1 63 Treatment Naïve 63 discontinued Viread 63 ATRA IV 63 dose intramuscular 63 4mg/kg 63 CDAD Clostridium difficile 63 stage IIIb 63 huC# DM4 63 Patients Treated With 63 IIa Clinical Trial 63 evaluable patients 63 DermaVir Patch 63 -#.# log# copies mL 63 generation NNRTI 63 essential thrombocythemia ET 63 Acneform rash occurred 63 hyperphenylalaninemia HPA due 63 plus prednisone 63 intradermal injections 63 HER2 positive metastatic breast 63 controlled multicenter 63 randomized #:#:# 63 genotype 1a 63 Phase #/#a trial 63 MGd 63 non metastatic resectable 63 bendamustine 63 Phase Ib study 63 metastatic renal cell 63 biliary tract cancer 63 receiving PEGINTRON 63 Multicenter Randomized 63 cIAI 63 midstage clinical 63 arsenic trioxide injection 63 unresectable Stage III 63 intravesical infusion therapy 63 administered subcutaneously 63 posaconazole 63 humanised monoclonal antibody 63 Myocet 63 OAB overactive bladder 63 metastatic colorectal carcinoma 63 clevidipine 63 chemotherapy cisplatin 63 EQUIP OB 63 lumiliximab 63 Tarceva TM 63 taxane resistant 63 hepatitis B immune globulin 63 estramustine 63 non nucleoside HCV 63 Anti Factor VIII 63 IMPDH inhibitor 63 liposomal formulation 63 adult chronic ITP 63 TDF FTC 63 Traficet EN 63 ancrod 63 Dose Escalation 63 candidemia 63 steroid refractory ulcerative 63 PEG Interferon lambda 63 mRCC 63 weekly intravenous infusions 63 refractory gout 63 Refractory Hodgkin Lymphoma 63 PEGylated interferon beta 1a 63 atypical Hemolytic Uremic Syndrome 63 AFREZZA TM 63 non constipating irritable 63 Degarelix 63 Metastatic Melanoma 63 Pruvel TM 63 RRMS patients 63 Cethromycin 63 R vitespen 63 evaluating Xcytrin 63 PDX pralatrexate 63 JVRS 63 Prulifloxacin 63 atazanavir ritonavir 63 Cariprazine 63 INCB# [001] 63 APTIVUS ritonavir 63 Vascugel 63 candidate XP# 63 MKC# 63 visceral metastases 63 anti CTLA 63 UNCERTAINTY OF FUTURE FINANCIAL 63 microbiological eradication 63 NMIBC 63 protease inhibitor PI 63 Treatment Experienced 63 advanced hepatocellular carcinoma 63 randomized #:# 63 RhuDex ® 63 anthracycline taxane 63 active comparator 63 AERAS-#/Crucell Ad# 63 telaprevir pegylated interferon 63 Zemplar Capsules 63 Ceflatonin R 63 Polymerase Inhibitor 63 PegIFN 63 invasive candidiasis 63 vaginal candidiasis 63 undetectable HBV DNA 63 orally inhaled migraine 63 TransVax TM 63 relapsing multiple sclerosis 63 ADP receptor antagonist 63 Stage IIB 63 REGN# 63 heFH 63 metastatic pancreatic 63 iniparib BSI 63 randomized controlled multicenter 63 alpha 2b 63 induced macular edema 63 dose cohorts 63 formerly LymphoStat B 63 FOLOTYN ® 63 riociguat 63 cancer neuroendocrine tumor 63 albiglutide 63 Intravitreal injections 63 gastrin analogue TT 63 Genasense ® 63 partial remissions 63 indolent follicular non 63 Protease Inhibitor 63 APTIVUS 63 rheumatoid arthritis psoriatic arthritis 63 Emtriva Viread 63 Rigel R# 63 monoclonal antibody conjugated 63 concurrent ITP 63 polymerase inhibitor 63 dacarbazine DTIC 63 PREZISTA r arm 63 includes investigational compounds 63 OncoVex 63 davunetide intranasal AL 63 CYP#A# CYP#D# 63 double blinded placebo 63 sarcoma melanoma 63 cytarabine daunorubicin 63 Methylnaltrexone 63 prostate cancer HRPC 63 CCR5 tropic 63 alpha 2a 63 PRT# 63 RhuDex R 63 recurrent glioblastoma 63 plus COPEGUS 63 pegylated interferon alfa 2b 63 receiving immunosuppressive therapy 63 Allovectin 7 ® 63 gemcitabine cisplatin 63 novel nucleoside analog 63 EmbraceAC 63 R lenalidomide 63 SCH # 63 fidaxomicin Phase 63 cEVR 63 Peg riba 63 sapacitabine CYC# 63 miconazole Lauriad ® 62 Efficacy Trial 62 APTIVUS r 62 evaluating picoplatin 62 trastuzumab DM1 T DM1 62 dasatinib Sprycel 62 EchoCRT 62 Study Evaluating 62 oral allopurinol 62 albiglutide currently 62 ZOLINZA 62 Phase III multicenter 62 celgosivir 62 XL# anticancer compounds 62 MORAb 62 unresectable HCC 62 mcg QD 62 HBeAg positive patients 62 oral talactoferrin 62 IMiDs 62 bortezomib Velcade R 62 previously untreated follicular 62 nucleoside analog 62 SUCCEED trial 62 randomized multicenter 62 sorafenib Nexavar 62 Atypical Hemolytic Uremic Syndrome 62 valsartan amlodipine 62 PEGylated anti 62 NSABP B 62 interferon alpha IFN 62 Phase #b/#a clinical 62 cetuximab Erbitux R 62 nausea dehydration dyspnea 62 randomized Phase 2b 62 Virulizin ® 62 Soft Tissue Sarcoma 62 COPEGUS therapy 62 recurrent NSCLC 62 Antiviral Therapy 62 urocortin 2 62 Initiates Phase 62 PHX# 62 HGS ETR1 62 transcriptase inhibitor NNRTI 62 evaluating MGCD# [002] 62 occlusion PAO 62 cytidine nucleoside analog 62 seroconverted 62 tipranavir r 62 peg IFN 62 Phase III Clinical Trial 62 TMC# r 62 mcg linaclotide 62 Adenoviral 62 bepotastine besilate nasal spray 62 Single Dose 62 PrevOnco 62 hypophosphatemia 62 COMBIVIR 62 IMA# 62 Lenocta TM 62 OPT CHF 62 Flu Cy 62 RANK Ligand inhibitor 62 dirucotide MBP# 62 Clevudine 62 Copegus ® 62 REG2 62 systemic anaplastic large 62 oral chemotherapeutic agent 62 anthracyclines taxanes 62 mcg dose 62 relapsed myeloma 62 evaluating Actimmune 62 BiTE R 62 Thiovir 62 AVONEX ® 62 AML MDS 62 either acutely decompensated 62 novel emulsion formulation 62 Vicriviroc 62 telaprevir dosing 62 randomized Phase IIb 62 #mg QD [001] 62 patients undergoing percutaneous 62 #mg BID [003] 62 administered intramuscularly 62 iobenguane 62 null responder 62 evaluating REVLIMID 62 personalized cellular immunotherapy 62 postmenopausal osteoporotic women 62 clinical trials SGN 62 pan histone deacetylase 62 BCIRG 62 achieve sustained virological 62 initiate Phase 1b 62 Diabetic Macular Edema 62 PNP inhibitor 62 Edge STudy 62 LHRH receptor positive 62 GEM OS2 62 Initiates Phase III 62 angiotensin analog 62 CONSERV 62 peginterferon alfa 62 resminostat 62 Xyfid TM 62 Investigational Treatment 62 interferon alfa 2b 62 neratinib 62 drug pipeline TAFA# 62 metastatic HRPC 62 viral kinetics 62 PREZISTA rtv 62 By JENNIFER LEARN 62 Pivotal Trial 62 Dacogen injection 62 Cloretazine ® 62 Infusion reactions 62 headache nasopharyngitis 62 oral dual endothelin 62 mCi kg 62 EXPLORE Xa 62 IFN alfa 62 Myocardial Infarction Study 62 chronic HBV 62 XIENCE V Stent System 62 cyclophosphamide doxorubicin vincristine 62 placebo controlled clinical 62 omacetaxine mepesuccinate 62 refractory metastatic colorectal cancer 62 saquinavir ritonavir 62 Phase 2b 62 deep venous thromboses 62 Phase #/#a 62 Linagliptin 62 CCR5 receptor antagonist 62 Zalypsis 62 Phase 2b Study 62 refractory metastatic 62 Syncria albiglutide 62 Vascular Disrupting Agent 62 Cytarabine Liposome Injection 62 velafermin 62 post herpetic neuralgia PHN 62 Severe Sepsis 62 valopicitabine 62 ENDEAVOR IV 62 BCG refractory carcinoma 62 liposome injection 62 venous stasis ulcers 62 immune globulin intravenous 62 lexidronam injection 62 Begins Dosing 62 Advanced Melanoma 62 CANCIDAS 62 phase 2a 62 paclitaxel poliglumex 62 mg eq 62 golimumab CNTO 62 Phase IIa trials 62 PEG Interferon alfa 62 Staccato prochlorperazine 62 diarrhea predominant irritable 62 Demonstrates Sustained 62 vesicular monoamine transporter 62 IV acetaminophen 62 PANVAC VF 62 arthritis PsA 62 NEUPOGEN 62 BENICAR HCT 62 refractory multiple myeloma 62 pharmacokinetic PK study 62 autoantibody positive 62 crizotinib PF # 62 relapsed leukemia 62 metastatic malignant 62 Alinia 62 nadroparin 62 sorafenib Nexavar R 62 Prospective Randomized 62 chlorambucil 62 complement inhibitor eculizumab 62 Phase IIb trials 62 SinuNase ™ 62 nucleotide analog polymerase inhibitor 62 Forodesine HCl 62 R entecavir 62 oral diclofenac 62 HQK 62 multicenter randomized controlled 62 Tanespimycin 62 teriflunomide 62 Randomized Double blind 62 purified inactivated vaccine 62 Atripla combines 62 MKC# MKC# PP 62 Newly Diagnosed Multiple Myeloma 62 selectively inhibit replication 62 EQUATE OB 62 rubella hepatitis 62 KRAS wild 62 peginterferon ribavirin 62 Phase 2b study 62 Omigard TM omiganan pentahydrochloride 62 Tesetaxel 62 lamivudine refractory patients 62 Blinatumomab 62 diagnosed GBM 62 #I TM# 62 EGFR TKI 62 Personalized Immunotherapy 62 Matrix Phase 2b 62 ADVANCE ILLUMINATE 62 REYATAZ r 62 Dementia Related Psychosis 62 CRp 62 #mg dosing group 62 Cimzia ® certolizumab pegol 62 Virologic 62 HIV uninfected 62 OMP #M# 62 TRO# 62 generation Hsp# inhibitor 62 Janus kinase 62 Epratuzumab 62 patients evaluable 62 highly emetogenic 62 clinical trials Archexin 62 cortisol synthesis 62 Fovea Pharmaceuticals subsidiary 62 NATRECOR ® 62 resistant hormone refractory 62 via intradermal injections 62 opioid naive 62 intra articular injection 62 Antiviral Activity 62 cardio renal 62 thrombin inhibiting aptamer 62 bortezomib refractory 62 INxin TM 62 pegylated liposomal doxorubicin 62 sunitinib Sutent ® 62 ascending doses 62 Demonstrates Positive 62 interferon alfa 2a 62 MVA MUC1 IL2 62 NO# [002] 62 Phase 2a clinical trials 62 mg BID 62 ribavirin therapy 62 Clolar ® 62 pomalidomide 62 MYDICAR ® 62 evaluating Vectibix 62 Pemetrexed 62 comparing alemtuzumab 62 baminercept 62 placebo dexamethasone 62 steroid refractory GvHD 62 PARGLUVA 62 steroid refractory 62 Enzastaurin 62 investigational monoclonal antibody 62 Commence Phase 62 diagnosed Ph + 62 patientswith 62 eosinophilic asthma 62 inhalations twice 62 pediatric Crohn disease 62 AzaSite Plus 62 3mg/kg 62 UPLYSO 62 mg kg dose 62 oncolytic virus therapies 62 Xcytrin R 61 ENABLE Phase 2 61 INCB# [003] 61 IMPACT DCM trial 61 IIb clinical trial 61 viral kinetic 61 receptor inhibitor 61 evaluating Prochymal 61 Vitaxin 61 pegylated interferon alfa 61 EUFLEXXA R 61 CRLX# 61 saline placebo 61 investigational compounds 61 AIR2 Trial 61 Prolongs Survival 61 pain palliation 61 peginterferon alfa 2a 61 trastuzumab emtansine T DM1 61 AGILECT R 61 PEGASYS ® 61 castrate resistant prostate cancer 61 Adjuvant Treatment 61 Rapid Virological Response 61 tumors GIST 61 Pegasys peginterferon alfa 2a 61 receiving highly emetogenic 61 undergoing androgen deprivation